JP2014515028A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515028A5
JP2014515028A5 JP2014508146A JP2014508146A JP2014515028A5 JP 2014515028 A5 JP2014515028 A5 JP 2014515028A5 JP 2014508146 A JP2014508146 A JP 2014508146A JP 2014508146 A JP2014508146 A JP 2014508146A JP 2014515028 A5 JP2014515028 A5 JP 2014515028A5
Authority
JP
Japan
Prior art keywords
composition
composition according
individual
administered
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014508146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515028A (ja
JP6038123B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/035626 external-priority patent/WO2012149451A1/en
Publication of JP2014515028A publication Critical patent/JP2014515028A/ja
Publication of JP2014515028A5 publication Critical patent/JP2014515028A5/ja
Application granted granted Critical
Publication of JP6038123B2 publication Critical patent/JP6038123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014508146A 2011-04-28 2012-04-27 ナノ粒子組成物の脈管内送達およびそれらの使用 Active JP6038123B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161518084P 2011-04-28 2011-04-28
US61/518,084 2011-04-28
US201161557851P 2011-11-09 2011-11-09
US61/557,851 2011-11-09
PCT/US2012/035626 WO2012149451A1 (en) 2011-04-28 2012-04-27 Intravascular delivery of nanoparticle compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016196955A Division JP6196719B2 (ja) 2011-04-28 2016-10-05 ナノ粒子組成物の脈管内送達およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2014515028A JP2014515028A (ja) 2014-06-26
JP2014515028A5 true JP2014515028A5 (cg-RX-API-DMAC7.html) 2015-06-18
JP6038123B2 JP6038123B2 (ja) 2016-12-07

Family

ID=47072793

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014508146A Active JP6038123B2 (ja) 2011-04-28 2012-04-27 ナノ粒子組成物の脈管内送達およびそれらの使用
JP2016196955A Active JP6196719B2 (ja) 2011-04-28 2016-10-05 ナノ粒子組成物の脈管内送達およびそれらの使用
JP2017157942A Active JP6427641B2 (ja) 2011-04-28 2017-08-18 ナノ粒子組成物の脈管内送達およびそれらの使用
JP2018203038A Pending JP2019011378A (ja) 2011-04-28 2018-10-29 ナノ粒子組成物の脈管内送達およびそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016196955A Active JP6196719B2 (ja) 2011-04-28 2016-10-05 ナノ粒子組成物の脈管内送達およびそれらの使用
JP2017157942A Active JP6427641B2 (ja) 2011-04-28 2017-08-18 ナノ粒子組成物の脈管内送達およびそれらの使用
JP2018203038A Pending JP2019011378A (ja) 2011-04-28 2018-10-29 ナノ粒子組成物の脈管内送達およびそれらの使用

Country Status (14)

Country Link
US (5) US9061014B2 (cg-RX-API-DMAC7.html)
EP (1) EP2701731B1 (cg-RX-API-DMAC7.html)
JP (4) JP6038123B2 (cg-RX-API-DMAC7.html)
KR (3) KR101970342B1 (cg-RX-API-DMAC7.html)
CN (3) CN109288789A (cg-RX-API-DMAC7.html)
AU (2) AU2012249371B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013027674A2 (cg-RX-API-DMAC7.html)
CA (2) CA2834040C (cg-RX-API-DMAC7.html)
ES (1) ES2819204T3 (cg-RX-API-DMAC7.html)
IL (2) IL229041B (cg-RX-API-DMAC7.html)
MX (1) MX354216B (cg-RX-API-DMAC7.html)
SG (2) SG10201606406PA (cg-RX-API-DMAC7.html)
WO (1) WO2012149451A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307875B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
JP5219518B2 (ja) 2004-12-09 2013-06-26 ザ ファウンドリー, エルエルシー 大動脈弁修復
AU2012201568B2 (en) * 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
SMT201900751T1 (it) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
US8399443B2 (en) 2009-04-22 2013-03-19 Mercator Medsystems, Inc. Treatment of hypertension by renal vascular delivery of guanethidine
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
CA2832311A1 (en) 2011-04-08 2012-11-29 Covidien Lp Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
ES2819204T3 (es) 2011-04-28 2021-04-15 Abraxis Bioscience Llc Administración intravascular de composiciones de nanopartículas y usos de las mismas
US9585960B2 (en) 2011-12-14 2017-03-07 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014138662A1 (en) 2013-03-08 2014-09-12 The Regents Of The University Of California Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN108024999A (zh) 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
EP4295906A3 (en) * 2016-09-22 2024-02-21 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
MX389962B (es) * 2016-09-28 2025-03-20 Abraxis Bioscience Llc Metodos para tratar trastornos mitocondriales y metabolicos.
US10576063B2 (en) 2017-05-26 2020-03-03 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
WO2019178231A1 (en) 2018-03-14 2019-09-19 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
CN112188892A (zh) 2018-03-20 2021-01-05 阿布拉科斯生物科学有限公司 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法
JP7335123B2 (ja) * 2019-10-07 2023-08-29 株式会社日本触媒 樹脂組成物、硬化性組成物、塗膜付き物品、塗膜付き物品の製造方法、コーティング剤及び積層塗膜付き基材の製造方法
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
CN1331321A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人丝/苏氨酸蛋白激酶16.17和编码这种多肽的多核苷酸
US6726923B2 (en) 2001-01-16 2004-04-27 Vascular Therapies, Llc Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US6547303B1 (en) 2001-08-13 2003-04-15 Johnson Controls Technology Company Pivoting seating system
US6860867B2 (en) 2001-09-20 2005-03-01 The Regents Of The University Of California Method of interventional surgery
US20060189941A1 (en) * 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
AU2003205315A1 (en) 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US20030207907A1 (en) * 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE416795T1 (de) * 2002-09-26 2008-12-15 Angiotech Int Ag Perivaskuläre hüllen
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US20040213770A1 (en) 2003-04-22 2004-10-28 Endobionics, Inc. Methods and systems for treating ischemic cardiac and other tissues
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US20090204104A1 (en) 2004-05-13 2009-08-13 Medtronic Vascular, Inc Methods for Compounding and Delivering a Therapeutic Agent to the Adventitia of a Vessel
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US7727554B2 (en) 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007014326A (es) * 2005-05-16 2008-02-11 Novartis Ag El uso de derivados de rapamicina para el tratamiento y/o la prevencion de trastornos cardiovasculares.
ES2541684T3 (es) * 2005-06-21 2015-07-23 Shire Regenerative Medicine, Inc. Crioconservación de material biocompatible
KR101457834B1 (ko) 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
US20080145439A1 (en) * 2006-07-31 2008-06-19 Neurosystec Corporation Nanoparticle drug formulations
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
RU2483714C2 (ru) 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
US9044385B2 (en) 2007-05-16 2015-06-02 Abbott Cardiovascular Systems Inc. Therapeutic compositions for targeted vessel delivery
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
ES2718612T3 (es) * 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2010068925A1 (en) 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20120189701A1 (en) 2009-03-13 2012-07-26 Desai Neil P Combination therapy with thiocolchicine derivatives
EP2416650B1 (en) 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
SMT201900751T1 (it) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
US8399443B2 (en) * 2009-04-22 2013-03-19 Mercator Medsystems, Inc. Treatment of hypertension by renal vascular delivery of guanethidine
ES2577024T3 (es) 2009-08-25 2016-07-12 Abraxis Bioscience, Llc Terapia combinada con composiciones de nanopartículas de taxano e inhibidores de Hedgehog
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
KR20130109025A (ko) 2010-06-02 2013-10-07 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR101850566B1 (ko) 2010-06-07 2018-04-19 아브락시스 바이오사이언스, 엘엘씨 증식성 질환의 치료를 위한 조합 치료 방법
ES2819204T3 (es) 2011-04-28 2021-04-15 Abraxis Bioscience Llc Administración intravascular de composiciones de nanopartículas y usos de las mismas
US9585960B2 (en) 2011-12-14 2017-03-07 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
HK1219231A1 (zh) 2013-03-13 2017-03-31 阿布拉科斯生物科学有限公司 治疗儿童实体瘤的方法
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
EP3313381A4 (en) 2015-06-29 2019-02-27 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
WO2017004267A1 (en) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
US20180256551A1 (en) 2015-06-29 2018-09-13 Abraxis Bioscience, Llc Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
CN108024999A (zh) 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Similar Documents

Publication Publication Date Title
JP2014515028A5 (cg-RX-API-DMAC7.html)
JP2017002083A5 (cg-RX-API-DMAC7.html)
KR102108959B1 (ko) 나노입자 조성물의 혈관내 전달 및 그의 용도
HRP20221100T1 (hr) Stabilna parenteralna formulacija nimopidina
JP2005504008A (ja) 過形成を治療するための組成物及び方法
Liu et al. Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial
JP2020521755A5 (cg-RX-API-DMAC7.html)
Jin et al. The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial
Armaganijan et al. Renal denervation using an irrigated catheter in patients with resistant hypertension: a promising strategy?
Ellenberger et al. Cardiovascular collapse due to massive pulmonary thromboembolism during orthotopic liver transplantation
Kim et al. Intercoronary communication between the circumflex and right coronary arteries coexisted with coronary vasospasm
Turan et al. Effectiveness of sublingual nitroglycerin before puncture compared with conventional intra-arterial nitroglycerin in transradial procedures: A randomized trial
CN116603116B (zh) 黄芩苷-铜复合纳米涂层鞘管及其制备方法与用途
Koutouzis et al. Percutaneous coronary intervention facilitated by extracorporeal membrane oxygenation support in a patient with cardiogenic shock
TWI631944B (zh) 氯硝柳胺及其衍生物的用途
HRP20200897T1 (hr) Parenteralna formulacija esmolola
Popescu et al. FIXE FULL-DOSE COMBINATION PERINDOPRIL/INDAPAMIDE/AMLODIPINE IN SEVERE DIABETIC HYPERTENSIVES
JP5589838B2 (ja) 血管性疾患の予防剤及び/又は治療剤
Truong et al. Recurrent intraoperative coronary artery spasm in a patient with coronary artery aneurysm
Ulucan 14 Recent Advances in
Kim et al. Sequential development of cardiac tamponade and subacute stent thrombosis after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a case report
Ványi et al. Metoprolol reduces ‘compensatory’coronary blood flow following occlusion of an adjacent branch without altering post-occlusion hyperaemia
Gülşen et al. Coronary vasospasm-induced periodic ventricular fibrillation and successful ablation through coronary stenting
Demir et al. Electroanatomic mapping-guided radiofrequency ablation of multifocal atrial tachycardia in a child/Multifokal atriyal tasikardi'li bir çocugun elektroanatomik haritalama sistemi esliginde radyofrekans kateter ablasyonu
Singh et al. Milrinone infusion: A therapeutic option in coronary vasospasm after primary percutaneous transluminal coronary angioplasty